参考文献：Cheson, B. D. (2003). Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. Journal of Clinical Oncology, 21(24), 4642–4649. doi:10.1200/jco.2003.04.036
PhaseI/IIとPhaseIIIでCRの定義はどう変わったのか？
Morphologic/ Cytogenetic/ Molecularでの違い
また、それぞれの中でも色々違いがあるようだし、臨床試験情報にはそこまで記載されていないようだしわからない。
「Response Criteria in AML」
Morphologic CR Varies by protocol
好中球 >1,000/μL、血小板 >100,000/μL、Bone Marrow Blasts(%) <5
Other: Transfusion EMD
Cytogenetic CR Varies by protocol
好中球 >1,000/μL、血小板 >100,000/μL、Bone Marrow Blasts(%) <5
Other: normal, EMD
Molecular CR Varies by protocol
好中球 >1,000/μL、血小板 >100,000/μL、Bone Marrow Blasts(%) <5
Other: negative, EMD
参考文献：Cheson, B. D. (2003). Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. Journal of Clinical Oncology, 21(24), 4642–4649. doi:10.1200/jco.2003.04.036